Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. The actions ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta Therapeutics’ Elevidys and Novartis ...

Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years.

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals get in the way of its progress. With recent indication additions, breast ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Tuesday reported first-quarter net income of $3.61 billion. On a per-share basis, the Basel, Switzerland-based company ...

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told ...

April 30 (Reuters) - Novartis (NOVN.S), opens new tab has agreed to buy Regulus Therapeutics (RGLS.O), opens new tab for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

(RTTNews) - Regulus Therapeutics (RGLS) has entered into an agreement and plan of merger with Novartis AG and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will ...

Swiss drug firm Novartis reported on Tuesday that it had generated a better-than-expected profit in the first three months of the year. Net sales were up 15% on a constant currency basis to $13.2 ...